SDGR (Schrödinger) Company Profit

Official company branding of Schrödinger (SDGR)

The visualized price action of Schrodinger, Inc. (SDGR) demonstrates business resilience, where software licenses for molecular analysis provide a stable revenue stream, and the indicator stands at -0.06. Schrodinger, Inc. (SDGR) develops physicochemical digital tools that help the biopharma sector mitigate risks and increase profits. The strategy relies on close partnerships with drug developers who jointly implement advanced computer modeling methods for new compounds.

SDGR Schrodinger, Inc. Net Profit (07/04/2022 - 10/31/2026)

Analytical breakdowns and data insights for company Schrödinger (SDGR)

- stock value and consensus price forecast:
Market Price Schrodinger Corp|SDGR - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Schrodinger Corp|SDGR - Total Company Value
- book capitalization information:
Net Assets per Share Schrödinger|SDGR - Book Capitalization|Market Cap to Net Assets Ratio schrodinger.com|SDGR - Company Total Assets
- debt and liquidity details:
All Debt to Shareholders' Equity Ratio Schrodinger, Inc.|SDGR - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Schrodinger Inc|SDGR - Company Debts|Debts to Book Value Schrodinger Corp|SDGR - Company Long-Term Debts|Company Short-Term Indebtedness Schrödinger|Interim Coverage Ratio schrodinger.com
- earnings and multiples data:
SDGR - Company Net Income
Basic company analysis:SDGR Schrodinger Corp
Manufactured products of Schrodinger Inc

Profit for Schrodinger, Inc. (SDGR) reflects the final financial result after deducting all operating expenses from revenue. This metric measures the business's ability to generate net cash flow, excluding incidental market fluctuations. By analyzing the company's balance of income and expenses, an investor assesses the effectiveness of monetizing quantum molecular modeling. Savings on physical drug trials directly impact final margins. Steady growth in this indicator confirms the viability of the AI strategy.

Direct competitors

Company Net Income Veeva Corp (VEEV)|DOCS (Doximity, Inc.) - Net Profit|Company Profit HQY (healthequity.com)|Company Net Income Waystar (WAY)|Net Financial Result CorVel Corp|Net Profit PRVA (Privia Health Corp)|HURN - Net Income|Certara, Inc. - Net Profit|Final Profit OMCL (omnicell.com)|GoodRx (GDRX) - Company Net Income|Phreesia Inc - Final Profit|Company Net Income Omada Health Corp|Company Net Income Evolent Corp EVH|Net Profit HSTM|definitivehc.com - Company Profit|Net Profit CCSI (Consensus Cloud Solutions, Inc.)|Net Financial Result agilon health, inc. (AGL)|ABSI - Company Net Income|SY (So-Young Corp) - Company Profit|NRC: Net Profit|Annual Net Income spok.com SPOK|OPRX (OptimizeRx) - Net Profit|Company Net Income TruBridge Inc TBRG|Company Net Income Simulations Plus Corp (SLP)|SOPH (sophiagenetics.com) - Final Profit|Health Catalyst, Inc. - Net Income|Final Profit CCLD|Research Solutions - Net Profit|Net Financial Result DLH Holdings Corp. DLHC|onemednet.com (ONMD) - Company Net Income|Company Profit SCNX|HCTI (Healthcare Triangle) - Net Profit|Net Income iSpecimen Corp (ISPC)|Net Income BFRG (Bullfrog AI Holdings)|Net Financial Result SCWorx Corp|Company Net Income LifeWallet MSPR|Net Financial Result iCoreConnect, Inc. (ICCT)|TRxADE HEALTH, Inc. - Net Profit|ORGS (orgenesis.com) - Company Profit|RCM: Net Profit|Annual Net Income Sharecare Inc. SHCR|Company Net Income Streamline Health Solutions Inc.|SYRA: Final Profit|Net Profit AMEH|Net Financial Result modeln.com|NextGen Healthcare, Inc. - Net Income